View the chart data
| Treatment | Participants with complete healing |
|---|---|
| Hovilpri | 63% |
| Investigator’s choice of available treatments | 34% |
The FDA approved Hovilpri on October 9 for adults with weakened immune systems whose herpes lesions resist standard treatment. That clears a major hurdle for Asahi Kasei’s recently acquired drug portfolio. The company expects U.S. availability before the end of 2026. [7][2]
This weekend analysis looks at what changes for the business. Approval gives Asahi Kasei a product it can bring to market, but patient access and sales still lie ahead. Its acquisition case now faces a commercial test.
A new option for a specific group of patients
Hovilpri, also called pritelivir, is an oral medicine. Its approval covers skin and mucosal lesions caused by herpes simplex virus, or HSV, in immunocompromised adults. The approved use is limited to lesions that have not responded to other therapies. [7]
That matters because difficult cases have often required intravenous treatment. A tablet offers a different route for eligible patients. The company says pritelivir blocks a different part of the virus’s machinery from the standard medicines. [2]
In the pivotal trial, 63% of Hovilpri recipients had all lesions heal by day 28. The comparison group reached 34%. Those results concern lesion healing in a defined patient group; HSV infection itself cannot be cured. [1]
Safety and prescribing limits still matter. The FDA identifies headache as the most common adverse reaction and flags drug interactions. This approval does not extend to every person living with herpes. [2]
“HOVILPRI offers a new oral treatment option for adult patients with a persistent, difficult-to-treat disease.”
FDA approval announcement · October 9, 2026 [2]
The acquisition now has a clearer path to sales
Asahi Kasei agreed in February to buy the drug’s developer, AiCuris, for approximately €780 million. It completed the acquisition in April. Friday’s decision turns a near-term approval prospect into an approved product. [3][4]
The acquired portfolio also includes royalty income from Prevymis and an experimental antiviral. That gives the deal more than one possible source of revenue, with different risks attached. Royalties, an approved drug and a development project are at different stages. [4]
In April, management projected AiCuris revenue of $500 million by fiscal 2030, excluding the experimental AIC468 program. That was a company forecast covering the portfolio, not Hovilpri sales already booked. Approval alone does not establish how quickly those revenues arrive. [4]
The timing of profit also deserves attention. Asahi Kasei expected the acquisition to contribute positively to operating income after acquisition-related amortization from fiscal 2028 onward. Amortization is the accounting expense that spreads the cost of acquired assets over time. A launch can precede that profit contribution. [3]
An existing sales platform meets a new launch
Asahi Kasei already has a U.S. commercial presence in kidney transplantation through its earlier Veloxis acquisition. In September, it announced a common Asahi Kasei Therapeutics brand and global management structure for its pharmaceutical businesses. That connects the new drug to a broader specialty-medicine platform. [5]
Existing experience with specialist care could help the company introduce another medicine for vulnerable patients. It cannot guarantee adoption. Prescribing decisions, access arrangements and the cost of commercialization will determine how much of the clinical opportunity becomes a business opportunity.
Investors’ exposure runs through Tokyo-listed parent Asahi Kasei. Hovilpri is one product within a group spanning healthcare, homes and materials. Its launch can change expectations for the pharmaceutical business without explaining the entire company’s earnings or share value. [6][2]
The next step is reaching patients
Hovilpri’s approval advances the acquisition from clinical promise toward commercial delivery. The next stated milestone is U.S. availability before year-end. How well Asahi Kasei delivers that launch, and how patients gain access, will shape the value of this new part of its drug portfolio. [2]